ABL

ABL Europe is the European subsidiary of ABL, Inc. - a leading CDMO and CRO harnessing decades of pioneering science and manufacturing expertise to drive the development of innovative therapies and vaccines. ABL has extensive experience working with diverse organizations - including industry, government, and academic entities - to support their quest in improving public health. ABL, Inc. - a subsidiary of the French bioindustrial group Institut Mérieux, which fights against infectious diseases and cancers, through the complementary approaches of its companies in the fields of diagnosis, immunotherapy, food safety and nutrition - maintains global GMP facilities meeting U.S. and European regulatory standards, providing GMP manufacture of virus-based oncolytic therapies, gene therapies, vaccines, and protein-based immunotherapeutic products. ABL's CDMO services include bulk drug substance, live virus fill/finish of drug product, process and assay development, and bioanalytical testing. As a CRO, ABL's immunologists use an integrated array of optimized immunology and molecular laboratory assay platforms, to extract immunological correlates of activity and response in both preclinical studies and clinical trials. To stay informed on the latest updates, please follow us on LinkedIn, Twitterand Facebookand subscribe to our mailing list.